# Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controlled Trial

> **NCT07205250** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **The General Hospital of Western Theater Command** · enrollment: 224 (estimated)

## Conditions studied

- Type B or Non-A Non-B Aortic Dissection;Thoracic Aortic Aneurysm

## Interventions

- **DRUG:** enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet)
- **OTHER:** a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets

## Key facts

- **NCT ID:** NCT07205250
- **Lead sponsor:** The General Hospital of Western Theater Command
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2028-01-20
- **Final completion:** 2028-09-20
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205250, "Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07205250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*